Recombinant Measles AIK-C Vaccine Strain Expressing the prM-E Antigen of Japanese Encephalitis Virus

An inactivated Japanese encephalitis virus (JEV) vaccine, which induces neutralizing antibodies, has been used for many years in Japan. In the present study, the JEV prM-E protein gene was cloned, inserted at the P/M junction of measles AIK-C cDNA, and an infectious virus was recovered. The JEV E pr...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 11; no. 3; p. e0150213
Main Authors Higuchi, Akira, Toriniwa, Hiroko, Komiya, Tomoyoshi, Nakayama, Tetsuo
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 01.03.2016
Public Library of Science (PLoS)
Subjects
Animals
Antibodies
Antibodies, Neutralizing
Antibodies, Viral - immunology
Antigens
Biology and Life Sciences
Cercopithecus aethiops
Cotton
E protein
Encephalitis
Encephalitis Virus, Japanese - immunology
Encephalitis, Japanese - prevention & control
Female
Genes
Genetic aspects
Genomes
Glycoproteins
HEK293 Cells
Humans
Immune response
Immunization
Immunoglobulins
Infections
Inoculation
Japanese encephalitis
Japanese Encephalitis Vaccines - immunology
Laboratories
Measles
Measles - prevention & control
Measles Vaccine - immunology
Measles vaccines
Measles virus - immunology
Medicine and Health Sciences
Neutralizing
Physiological aspects
Prevention
Proteins
Rats
Research and Analysis Methods
Respiratory syncytial virus
Vaccine development
Vaccines
Vaccines, Synthetic - immunology
Vector-borne diseases
Vero Cells
Viral antigens
Viral infections
Viruses
Japan
China
Online AccessGet full text

Cover

More Information
Summary:An inactivated Japanese encephalitis virus (JEV) vaccine, which induces neutralizing antibodies, has been used for many years in Japan. In the present study, the JEV prM-E protein gene was cloned, inserted at the P/M junction of measles AIK-C cDNA, and an infectious virus was recovered. The JEV E protein was expressed in B95a cells infected with the recombinant virus. Cotton rats were inoculated with recombinant virus. Measles PA antibodies were detected three weeks after immunization. Neutralizing antibodies against JEV developed one week after inoculation, and EIA antibodies were detected three weeks after immunization. The measles AIK-C-based recombinant virus simultaneously induced measles and JEV immune responses, and may be a candidate for infant vaccines. Therefore, the present strategy of recombinant viruses based on a measles vaccine vector would be applicable to the platform for vaccine development.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Conceived and designed the experiments: TN. Performed the experiments: AH HT TN. Analyzed the data: TK TN. Contributed reagents/materials/analysis tools: TN. Wrote the paper: TN. Performed the present experiments during his master course: AH. Performed the detection of NT and EIA antibodies against JEV: HT TK. Developed measles vaccine vector and organized the study and prepared manuscript: TN.
Competing Interests: On behalf of all co-authors, the following competing interests are declared: TN had research funding from Daiichi Sankyo. AH is an employee of Kitasato-Daiichi Sankyo Vaccine, Division of Vaccine Production. HT and TK are staff members of Kitasato-Daiichi Sankyo Vaccine, Division of Vaccine Development. Daiichi Sankyo provided JEV vaccine strain. There are no patents, products in development or marketed products to declare. This did not alter the adherence to all the PLOS ONE policies on sharing data and materials.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0150213